

The present invention is applicable in the pharmaceutical industry and relates to the use of molsidomine or a pharmaceutically acceptable salt thereof, particularly in the form of a sustained-release solid oral composition effective for 24 hours, for producing a drug for preventing or controlling atherosclerosis.